Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Sam Schulman(Thrombosis and Atherosclerosis Research Institute), Samuel Z. Goldhaber(Brigham and Women's Hospital), Sebastian Schellong(Städtisches Klinikum Dresden), Anne Mathilde Kvamme(Boehringer Ingelheim (Norway)), David Baanstra(Boehringer Ingelheim (Netherlands)), Ajay K. Kakkar(Thrombosis Research Institute), Patrick Mismetti, Clive Kearon(McMaster University), Henry Eriksson(Sahlgrenska University Hospital), Jeffrey Friedman(Boehringer Ingelheim (United States))
Cited by 988
Related Papers
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
|Journal of Thrombosis and Haemostasis|2005|4.9k
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
|Journal of Thrombosis and Haemostasis|2009|3.8k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Prevention of VTE in Nonsurgical Patients
|CHEST Journal|2012|2.7k
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
|New England Journal of Medicine|2009|2.6k